JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.34 0.75

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.32

Max

1.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-103K -6.6M
Werknemers	42

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+175.74% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	25M 98M
Vorige openingsprijs	0.59
Vorige sluitingsprijs	1.34

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2026, 21:36 UTC

Acquisities, Fusies, Overnames

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mei 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mei 2026, 18:37 UTC

Belangrijke Marktbewegers

Senseonic Shares Slide on Underwritten Offering Price

1 mei 2026, 16:46 UTC

Belangrijke Marktbewegers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mei 2026, 19:57 UTC

Acquisities, Fusies, Overnames

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mei 2026, 15:24 UTC

Winsten

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mei 2026, 12:46 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mei 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 mei 2026, 20:42 UTC

Winsten

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mei 2026, 19:33 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 mei 2026, 19:33 UTC

Marktinformatie

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mei 2026, 19:18 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mei 2026, 19:13 UTC

Marktinformatie

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mei 2026, 18:36 UTC

Winsten

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mei 2026, 18:35 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mei 2026, 18:28 UTC

Winsten

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mei 2026, 18:27 UTC

Marktinformatie

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mei 2026, 18:14 UTC

Acquisities, Fusies, Overnames

Barclays Completes Acquisition of Best Egg

1 mei 2026, 18:04 UTC

Winsten

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mei 2026, 17:43 UTC

Marktinformatie

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mei 2026, 17:37 UTC

Marktinformatie

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mei 2026, 17:30 UTC

Marktinformatie

Winsten

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mei 2026, 17:28 UTC

Marktinformatie

Winsten

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mei 2026, 17:21 UTC

Marktinformatie

Winsten

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mei 2026, 17:19 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mei 2026, 16:38 UTC

Marktinformatie

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mei 2026, 16:23 UTC

Acquisities, Fusies, Overnames

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

175.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.75 USD 175.74%

Hoogste 4 USD

Laagste 3.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.